Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Hospital acquired infections (HAI) diagnostics industry 3600 synopsis, 2018 – 2032
2.2 Business trends
2.3 Regional trends
2.4 Product trends
2.5 Test type trends
2.6 Infection type trends
2.7 End-use trends
Chapter 3 Hospital Acquired Infections (HAI) Diagnostics Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of hospital acquired infections (HAI)
3.2.1.2 Technological advancements
3.2.1.3 Rising demand for point-of-care (POC) testing
3.2.1.4 Growing demand for early diagnosis and prevention of hospital acquired diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory policies
3.2.2.2 Lack of awareness regarding hospital acquired infections in low and middle income nations
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By test type
3.3.3 By infection type
3.3.4 By end use
3.4 COVID- 19 impact analysis
3.5 Pricing analysis, 2022
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Technology landscape
3.8 Reimbursement scenario
3.9 Future market trends
3.10 Gap analysis
3.11 Porter's analysis
3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis, 2022
4.6 Strategy dashboard, 2022
Chapter 5 Hospital Acquired Infections (HAI) Diagnostics Market Size and Forecast, By Product (USD Million & Units)
5.1 Key trends, by product
5.2 Reagents
5.3 Analyzers
Chapter 6 Hospital Acquired Infections (HAI) Diagnostics Market Size and Forecast, By Test Type (USD Million)
6.1 Key trends, by test type
6.2 Traditional Diagnostic Test
6.3 Molecular Diagnostic Assay
6.4 Immunoassays
6.5 Mass Spectrometry
6.6 Others
Chapter 7 Hospital Acquired Infections (HAI) Diagnostics Market Size and Forecast, By Infection Type (USD Million)
7.1 Key trends, by infection type
7.2 Urinary Tract Infections (UTIs)
7.3 Surgical Site Infections (SSIs)
7.4 Respiratory Infections
7.5 Bloodstream Infections
7.6 Gastrointestinal Infections
7.7 Others
Chapter 8 Hospital Acquired Infections (HAI) Diagnostics Market Size and Forecast, By End-use (USD Million)
8.1 Key trends, by end-use
8.2 Hospitals
8.3 Diagnostic Laboratories
8.4 Research Institutes
8.5 Others
Chapter 9 Hospital Acquired Infections (HAI) Diagnostics Market Size and Forecast, By Region (USD Million & Units)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Sweden
9.3.8 The Netherlands
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Thailand
9.4.7 Indonesia
9.4.8 Philippines
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Columbia
9.5.5 Chile
9.5.6 Peru
9.6 MEA
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Israel
9.6.5 Turkey
9.6.6 Iran
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Bayer
10.3 Becton Dickinson And Company
10.4 Biomérieux
10.5 Danaher Corporation
10.6 Ecolab
10.7 Hologic, Inc.
10.8 Johnson & Johnson
10.9 Merck
10.10 Pfizer Inc.
10.11 Roche
10.12 Siemens Healthcare
10.13 Steris Plc
10.14 Thermo Fisher Scientific
